Signal transducer and activator of transcription 3
Signal transducer and activator of transcription 3 (STAT3) is a gene and signaling mediator investigated in studies of inflammation, cancer, bone remodeling, kidney injury, neural injury, metabolism, and immune regulation.
Signal transducer and activator of transcription 3 (STAT3) is a gene and signaling mediator investigated in studies of inflammation, cancer, bone remodeling, kidney injury, neural injury, metabolism, and immune regulation. The provided literature places STAT3 within several interconnected signaling networks, including JAK2–STAT3, SRC–ERK/STAT3, FOXO1/STAT3, STAT3/NF-κB/NFATc1, and PD-L1–STAT3 pathways. Across these contexts, STAT3 activity is assessed through phosphorylation, gene-expression changes, pathway modulation, and interactions with processes such as autophagy, apoptosis, glycolysis, and osteoclastogenesis.
STAT3 is also examined as a pharmacological target. The reported approaches include small-molecule pathway inhibitors, natural products, metabolic drugs, and cell-based interventions. The associated studies do not define a single disease-specific therapeutic role; rather, they extend the broader theme of STAT3 signaling across diseases, with STAT3-linked mechanisms being explored in lymphoma, esophageal cancer, non-small cell lung cancer, osteoporosis, renal injury, spina bifida-associated neuronal injury, and immune-mediated intestinal disease.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
23 papers study signal transducer and activator of transcription 3 directly. The themes below are drawn from those 23. 1 paradigm shift and 1 new direction follow.
-
JAK/STAT3 Therapeutic Modulation : Therapeutic modulation of JAK/STAT3 is being pursued across renal, cardiac, vascular, thyroid and lymphoma settings. IL-6/JAK2, HIF-1α, AKT1/TLR4 and autophagy recur as links to fibrosis, inflammation, mitochondrial injury and tumor growth. 8 papers · 34.8%
-
Cancer Progression and Resistance : Cancer progression and treatment resistance are being addressed through immune and metabolic rewiring rather than STAT3 inhibition alone. PD-L1–PDK4/GLS signaling, SPP1 repression, SAT1-mediated spermine catabolism and NQO1/STAT3/HDAC targeting recur alongside anti-PD-1 and enzalutamide sensitivity. 8 papers · 34.8%
-
NF-κB and STAT3 Inflammation : Small molecules and natural products are being developed to suppress coordinated NF-κB/STAT3 inflammatory signaling in colitis, liver failure, osteoporosis and triple-negative breast cancer. iNOS, NFATc1 and osteoclast differentiation recur as therapeutic endpoints. 5 papers · 21.7%
-
Others — STAT3-Linked Tissue Injury : FOXO1/STAT3-regulated autophagy is linked to neuronal injury in spina bifida, whereas extracellular-vesicle miRNAs drive monocyte-endothelial crosstalk in diabetic kidney injury. The settings share injury-associated STAT3 biology but pursue distinct mechanisms. 2 papers · 8.7%
STAT3 activation can mediate tissue protection rather than simply drive pathology
The spina bifida rat study of amniotic fluid stem cells and the obese-mouse kidney study of dapagliflozin place enhanced STAT3 signaling downstream of treatments that alleviate tissue injury and renal disease, respectively 42723550Sep 42364320Jun. The prevailing assumption in the set is that pathological STAT3 activity should be suppressed, but these studies instead associate STAT3 activation or phosphorylation with autophagy-linked neural protection and SLC5A2-SRC-ERK/STAT3-mediated renoprotection. This shifts the interpretation of STAT3 from a uniformly harmful therapeutic target to a context-dependent pathway whose activation can contribute to beneficial repair or organ protection.
STAT3 inhibition is presented as a trigger of immunogenic cell death through coordinated effects on stemness and cellular stress
The multiple-myeloma study of STAT3 inhibition reports that blocking STAT3 eliminates stem-like cells while eliciting hallmarks of immunogenic cell death 42740603Sep. Unlike the other papers, which use STAT3 chiefly as a mediator of tumor growth, inflammatory signaling, tissue injury, or osteoclast differentiation, this study assigns STAT3 a role in coupling tumor-cell stemness and integrated stress responses to the induction of antitumor immunity. The result opens a direction in which STAT3 inhibition is evaluated not only for direct tumor suppression but also for its capacity to make malignant cells immunogenic.
Recent Findings on signal transducer and activator of transcription 3
JAK/STAT3 Disease Signaling: Yupingfeng San, hydrogen sulfide, and digoxin reduced inflammatory or fibrotic injury by suppressing IL-6/JAK/STAT3 or HIF-1α–STAT3 signaling 42097338May42259239Jun42497831Jul. Dapagliflozin blocked an SLC5A2-SRC-ERK/oxidative stress-STAT3 injury network in proximal tubule S1 cells and restored renal paracrine signaling 42364320Jun. Guanxin Ⅱ also modulated STAT3 within an AKT1-STAT3-TLR4 axis while activating ATG3-mediated autophagy in atherosclerosis with depression-like behavior 42162760May. Other studies instead used STAT3 inhibition for cancer, with AH-26 stabilizing STAT3 while inhibiting its phosphorylation and CDK8/19 inhibitors disrupting an autocrine IL-6-JAK2-STAT3 loop in lymphoma 42322913Jun42696577Sep. ONSMP illustrates context-dependent signaling, increasing STAT3 phosphorylation within a cGMP-PKG-GPX4 pathway while reducing ferroptosis and myocardial injury 42144210May.
Metabolic and Immune Resistance: SAT1-driven spermine catabolism activated JAK1/STAT3 and reduced enzalutamide sensitivity in prostate cancer, while PD-L1-induced PDK4/GLS activity reinforced STAT3-dependent macrophage immunosuppression 42744967Sep42686373Sep. Metabolic or immune rewiring also shaped treatment response through STAT1-related mechanisms, including mutant p53-FOXA1-SPP1 control of MDSC recruitment and FGF21-adiponectin restoration of hepatic leptin receptor signaling 42726875Sep42462724Jul. STAT1 expression similarly marked lymph node metastasis and promoted invasion, migration, epithelial-mesenchymal transition, and ECM-related gene expression in esophageal squamous cell carcinoma 42700277Sep. STAT3 inhibition eliminated multiple myeloma stem-like cells and induced hallmarks of immunogenic cell death, although in vivo validation remains necessary 42740603Sep. Drug development is moving toward combinations, including NQO1/STAT3/HDAC targeting and SPP1 blockade with anti-PD-1, while JAK inhibitors may select resistant clones in refractory celiac disease 42341572Jun42726875Sep42002153Apr.
Inflammatory NF-κB/STAT3 Signaling: Bruceine D and BP-1-102 inhibited STAT3, NF-κB, and NFATc1 signaling to suppress RANKL-induced osteoclast differentiation and protect ovariectomized mice from bone loss 42684554Sep42308767Jun. Clovamide analogue 10E reduced NF-κB/STAT3 activation, inflammatory mediator expression, and barrier damage in experimental colitis 42308787Jun. Compound 27 similarly inhibited NF-κB and STAT3 phosphorylation and protected mice from TLR4-dependent acute liver failure 42308786Jun. Dual-pathway inhibition also produced an antimetastatic TNBC lead, but related imidazole analogues showed activity linked to severe cytotoxicity 42308789Jun. These findings support natural-product analogues and dual inhibitors as preclinical leads, with selectivity and therapeutic-window differences guiding further optimization.
STAT3 in Tissue Injury: Amniotic fluid stem cells improved neuronal injury-related changes in spina bifida rats by increasing autophagy through the FOXO1/STAT3 axis 42723550Sep. FOXO1 overexpression or STAT3 inhibition weakened these effects, whereas FOXO1 knockdown strengthened them, linking pathway direction to the autophagic response. In diabetic kidney disease, extracellular-vesicle miRNAs drove reciprocal monocyte-endothelial injury through miR-191-3p/CYLD/NF-κB and miR-615-3p/IFNGR2/STAT3 axes 42275918Jun. Targeting these molecules partially relieved renal damage, but their diagnostic and therapeutic value still requires validation 42275918Jun.
Written from 23 PubMed abstracts, each one cited by PMID above. Published: 2026-09-12. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.